Hjem › Tripelnegativ brystkreft › Minnesota › Minneapolis
Kliniske studier for Tripelnegativ brystkreft i Minneapolis, MN
8 studier for Tripelnegativ brystkreft søker deltakere på steder i og rundt Minneapolis (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
PRE-ISPY Phase I/II Oncology Platform Program
RekruttererFase 1/2
- University of Minnesota Masonic Cancer Center, Minneapolis
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
RekruttererFase 3
- Allina Health Cancer Institute ( Site 0069), Minneapolis
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
RekruttererFase 3
- Metro-Minnesota Community Clinical Oncology ( Site 0031), Saint Louis Park · 5 mi unna
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
RekruttererFase 3
- Virginia Piper Cancer Center (Allina Health), Minneapolis
- University of Minnesota Medical Center, Fairview, Minneapolis
- Metro Minnesota Community Oncology, Saint Louis Park · 5 mi unna
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
RekruttererFase 1
- Normunity Investigational Site, Minneapolis
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
RekruttererFase 2/3
- Local Institution - 0372, Minneapolis
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
RekruttererFase 1
- M Health Fairview University of Minnesota Medical Center - East Bank /ID# 276200, Minneapolis
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RekruttererFase 2
- University of Minnesota, Minneapolis
- Metro Minnesota Community Oncology Research Consortium, Hennepin County Medical Center, Saint Louis Park · 5 mi unna
Tripelnegativ brystkreft-studier i andre byer
- Houston, TX42 studier
- New York City, NY31 studier
- Nashville, TN28 studier
- Los Angeles, CA27 studier
- Boston, MA26 studier
- San Antonio, TX23 studier
- St. Louis, MO21 studier
- Arlington, VA20 studier
- Atlanta, GA20 studier
- Dallas, TX18 studier
- Chicago, IL16 studier
- Columbus, OH16 studier
Andre studier i Minneapolis
- Ikke-småcellet lungekreft27 studier
- Brystkreft27 studier
- Eggstokkreft24 studier
- Prostatakreft23 studier
- Kreft (alle typer)22 studier
- Hjertesvikt21 studier
- Akut myelogen leukemi20 studier
- Lungekreft20 studier
- Kolorektal kreft19 studier
- Endometriekreft18 studier
- Parkinsons sykdom17 studier
- Kardiovaskulær sykdom15 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.